Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.25 USD
Change Today -0.10 / -2.99%
Volume 515.1K
ONTY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

oncothyreon inc (ONTY) Snapshot

Open
$3.29
Previous Close
$3.35
Day High
$3.38
Day Low
$3.22
52 Week High
06/1/15 - $4.69
52 Week Low
05/5/15 - $1.41
Market Cap
308.5M
Average Volume 10 Days
1.1M
EPS TTM
$-0.58
Shares Outstanding
94.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOTHYREON INC (ONTY)

oncothyreon inc (ONTY) Related Businessweek News

No Related Businessweek News Found

oncothyreon inc (ONTY) Details

Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer and rare diseases. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; collaboration with Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

49 Employees
Last Reported Date: 03/10/15
Founded in 1985

oncothyreon inc (ONTY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $276.0K
Chief Operating Officer
Total Annual Compensation: $310.0K
Chief Medical Officer
Total Annual Compensation: $355.0K
Chief Scientific Officer
Total Annual Compensation: $270.5K
Compensation as of Fiscal Year 2014.

oncothyreon inc (ONTY) Key Developments

Oncothyreon Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for 2015

Oncothyreon Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. Net loss for the three months ended June 30, 2015 was $10.9 million, or $0.11 per basic and diluted share, compared with a net loss of $6.0 million, or $0.09 per basic and diluted share, for the comparable period in 2014. The $4.9 million increase in net loss was primarily attributable to the difference in the change in the fair value of warrant liability of $4.3 million. The increase in net loss was also due to increases in research and development expenses of $0.3 million and increases in general and administrative expenses of $0.2 million. Loss from operations was $8.337 million against $7.797 million a year ago. Net loss for the six months ended June 30, 2015 was $18.8 million, or $0.19 per basic and diluted share, compared with a net loss of $15.6 million, or $0.22 per basic and diluted share, for the comparable period in 2014. The $3.2 million increase in net loss was attributable to the difference in the change in the fair value of warrant liability of $1.7 million, increases in research and development expenses of $1.3 million and increases in general and administrative expenses of $0.2 million. Loss from operations was $16.416 million against $14.957 million a year ago. The company currently expects operating expenses in 2015 to be lower than in 2014, which included the upfront payment to Array BioPharma Inc. for the exclusive license to ONT-380. The company currently expects cash used in operations in 2015 to be approximately $32.0 - $34.0 million.

Oncothyreon Inc, Q2 2015 Earnings Call, Aug 06, 2015

Oncothyreon Inc, Q2 2015 Earnings Call, Aug 06, 2015

Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting

Oncothyreon Inc. announced the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The first presentation updated data from the Phase 1b trial of ONT-380 in combination with Xeloda® (capecitabine)and Herceptin® (trastuzumab) in third line treatment of HER2-positive metastatic breast cancer. The data support Oncothyreon's plans to initiate a blinded, randomized, placebo-controlled Phase 2 trial in this indication. The second presentation focused on the role of ONT-380 in the treatment of HER2-positive breast cancer central nervous system (CNS) metastases. The Phase 1b trial of ONT-380 in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) is a parallel dose escalation study in patients previously treated with Herceptin and Kadcyla® (ado-trastuzumab emtansine or TDM-1) for metastatic breast cancer. Data were presented for 32 patients, including seven in the ONT-380 plus Xeloda cohort, 13 in the ONT-380 plus Herceptin cohort and 12 in the ONT-380 plus Xeloda and Herceptin cohort. Twenty-seven of the patients were evaluable for best overall response using RECIST 1.1 criteria. Considering the three cohorts together, a complete response (CR) was seen in two patients, a partial response (PR) in 12 patients, stable disease (SD) in nine patients and progressive disease (PD) in four patients. ONT-380 has been well tolerated in both Phase 1b trials. The most common adverse events included diarrhea, nausea, constipation, fatigue, dyspepsia, headache and vomiting. Most adverse events were grade 1 or 2 in severity. Laboratory abnormalities included asymptomatic elevated liver function tests, which were more common in patients also receiving Kadcyla. No grade 3 diarrhea was seen in either trial at the recommended dose of ONT-380; anti-diarrheal prophylaxis was not a study requirement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $3.25 USD -0.10

ONTY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTY.
View Industry Companies
 

Industry Analysis

ONTY

Industry Average

Valuation ONTY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOTHYREON INC, please visit www.oncothyreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.